You are here

  • Home
  • Archive
  • Volume 80, Issue 8
  • Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Citation Tools

Article menu
XML
Spondyloarthritis
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Landewé RB, Gensler LS, Poddubnyy D on behalf of the COAST-Y study group, et al
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
Annals of the Rheumatic Diseases 2021;80:1022-1030.